Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.44 |
| ▸ | PRCP | P42785 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6251671 | 0.98 | SIGMAR1 (0.50) | SIGMAR1SRD5A1HTR2CIDO1 | |
| Hydrochloric Acid SCHEMBL6249117 | 0.88 | SIGMAR1 (0.49) | SIGMAR1PRCPIDO1 | |
| SCHEMBL10724594 | 0.86 | HTR2A (0.49) | SIGMAR1PRCPHTR2CHTR2AHTR2B | |
| SCHEMBL9307217 | 0.82 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL9307226 | 0.82 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL9307221 | 0.82 | SIGMAR1 (0.50) | SIGMAR1HTR2CHTR2AHTR2B | |
| SCHEMBL11460515 | 0.81 | SIGMAR1 (0.56) | SIGMAR1SRD5A1PRCPHTR2CHTR2A | |
| SCHEMBL28748526 | 0.80 | PRCP (0.46) | SIGMAR1SRD5A1PRCPHTR2CHTR2A | |
| SCHEMBL11671198 | 0.80 | SRD5A1 (0.55) | SIGMAR1SRD5A1HTR2AIDO1PDPK1 | |
| SCHEMBL5860592 | 0.79 | HTR2C (0.45) | SIGMAR1PRCPHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566734-B2 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-07-28 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| CN-1204121-C | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2005-06-01 | — | — | CN | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-1003743-A4 | 3,3-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6124319-A | TREATING INFLAMMATORY AND IMMUNOREGULATORY DISORDERS AND DISEASES, INCLUDING ASTHMA AND ALLERGIC DISEASES, AUTOIMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS | MERCK & CO., INC. (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0745591-B1 | Indanylpiperidines as melatonergic agents | BRISTOL MYERS SQUIBB CO (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1003743-A1 | 3,3-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| CN-1253547-A | 1,4-substituted cyclic amine derivatives | EISAI CO LTD (JP) | 2000-05-17 | — | — | CN | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5807865-A | 3,3-disubstituted piperidine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1998031364-A1 | 3,3-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-07-23 | — | — | WO | disclosed |
| US-5703239-A | CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| EP-0745591-A1 | Indanylpiperidines as melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5114949-A | Treating disorders associated with 5HT uptake | RHONE-POULENC SANTE (FR) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | SIGMAR1 1200/4885SRD5A1 623/4885PRCP 3744/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | SIGMAR1 523/4885SRD5A1 1028/4885PRCP 3526/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | SIGMAR1 505/4885SRD5A1 2463/4885PRCP 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.